DFP-11207

• Description :

  DFP-11207 is an orally active fluoropyrimidine cytotoxic agent. DFP-11207 combines a 5-FU (HY-90006) pro-drug with a reversible DPD inhibitor and a potent inhibitor of OPRT, resulting in enhanced pharmacological activity of 5-FU with decreased gastrointestinal and myelosuppressive toxicities. DFP-11207 can be used for the research of cancer [1].

• CAS Number :

  [1296177-16-6]

• UNSPSC :

  12352005

• Target :

  Dihydropyrimidine Dehydrogenase (DPD) ; Nucleoside Antimetabolite/Analog

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

• Field of Research :

  Cancer

• Smiles :

  O=C(C1=CC(OC(CC)=O)=NC(OC(CC)=O)=C1)OC2=CC(OC(C3=CC=CC(C(N(C(N(COCC)C=C4F)=O)C4=O)=O)=C3)=O)=NC=C2Cl

• Molecular Formula :

  C32H26ClFN4O12

• Molecular Weight :

  713.02

• References & Citations :

  [1]Ajani JA, et al. Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs. 2020 Dec;38 (6) :1763-1773.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1